Skip to main content

Advertisement

SpringerLink
Log in

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor. This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma.

Method

A 3+3 study design was utilized at predefined dose levels. Polymorphisms in the TS enhancer region and XPD enzyme were investigated as potential predictors of efficacy and toxicity.

Results

Fourteen patients received 76 cycles of treatment. At the highest dose level (OSI-7904L 9 mg/m2, oxaliplatin 130 mg/m2) investigated, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose reductions. The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a TS inhibitor/oxaliplatin combination regimen. PK analysis showed high interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin. Partial radiological responses were documented in two patients.

Conclusions

The recommended regimen for further investigation is OSI-7904L 9 mg/m2 and oxaliplatin 130 mg/m2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Colorectal Cancer Collaborative Group (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321:531–535

    Article  Google Scholar 

  2. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomized trial. Lancet 355:1041–1047

    Article  PubMed  CAS  Google Scholar 

  3. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment for metastatic colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  4. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

    Article  PubMed  CAS  Google Scholar 

  5. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338

    Article  PubMed  CAS  Google Scholar 

  6. De Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815

    PubMed  Google Scholar 

  7. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 19:4097–4106

    PubMed  Google Scholar 

  8. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/ tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616

    Article  PubMed  CAS  Google Scholar 

  9. Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW (2004) Pharmacokinetics, safety and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Ther 309:894–902

    Article  PubMed  CAS  Google Scholar 

  10. Beutel G, Glen H, Schöffski P et al (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res 11:5487–5495

    Article  PubMed  CAS  Google Scholar 

  11. Winski S, Nilsson C, Brown E et al (2002) In vivo antitumor efficacy of liposomal OSI-7904L in human tumor xenografts. NCI-EORTC-AACR Molecular targets and cancer therapeutics meeting, 2002 Abstract 119

  12. Pendyala L, Leichman CG, Clark K et al (2001) Oxaliplatin influences the intra-tumoral expression of γ-glutamylcysteine synthetase and thymidylate synthase genes in patients with esophagus cancer. Proc Am Soc Clin Oncol 20, 351a

  13. Kawakami K, Omura K, Kanehira E et al (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249–3252

    PubMed  CAS  Google Scholar 

  14. Chen J, Hunter DJ, Stampfer MJ et al (2003) Polymorphism in the thymidylate synthase promoter enhancer region modifies risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 12:958–962

    PubMed  CAS  Google Scholar 

  15. Mandola MV, Stoehlmacher J, Muller-Weeks S et al (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898–2904

    PubMed  CAS  Google Scholar 

  16. Morganti M, Ciantelli M, Giglioni B et al (2005) Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176–2183

    Article  PubMed  CAS  Google Scholar 

  17. Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594–2601

    Article  PubMed  CAS  Google Scholar 

  18. Spitz MR, Wu X, Wang Y et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354–1357

    PubMed  CAS  Google Scholar 

  19. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354

    PubMed  CAS  Google Scholar 

  20. Cancer Therapy Evaluation Programme (2003) Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. December 12 2003. (http://www.ctep.cancer.gov/reporting/ctc_v3.0)

  21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  22. Falk SJ, Anthoney A, Eatock M et al (2006) Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 95:450–456

    Article  PubMed  CAS  Google Scholar 

  23. Graham MA, Lockwood GF, Greenslade D et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–1218

    PubMed  CAS  Google Scholar 

  24. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303

    Article  PubMed  CAS  Google Scholar 

  25. Maindrault-Goebel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000–1005

    Article  PubMed  CAS  Google Scholar 

  26. Ford HER, Mitchell F, Cunningham D et al (2002) Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8:103–109

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. D. W. Drolet for his assistance in the pharmacokinetic analyses.

Funding source

The study sponsor was OSI Pharmaceuticals Inc. Study design, data collection, interpretation and decision to submit the manuscript for publication were undertaken by the EORTC in conjunction with the authors.

Conflict of interest statement

J. Chick is an employee of OSI Pharmaceutical Inc. and hold share options in this company. None of the other authors have any conflict of interest.

Author information

Authors and Affiliations

  1. Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK

    A. R. Clamp, J. W. Valle & G. C. Jayson

  2. Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany

    P. Schöffski

  3. Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, BT9 7AB, UK

    R. H. Wilson

  4. EORTC New Drug Development Program (NDDP), Brussels, Belgium

    S. Marreaud, A.-S. Govaerts, M. Debois, D. Lacombe & C. Twelves

  5. OSI Pharmaceuticals Inc, Oxford, UK

    J. Chick

Authors
  1. A. R. Clamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Schöffski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. W. Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. H. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Marreaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A.-S. Govaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Debois
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Lacombe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Twelves
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Chick
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. C. Jayson
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EORTC New Drug Development Group

Corresponding author

Correspondence to A. R. Clamp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clamp, A.R., Schöffski, P., Valle, J.W. et al. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 61, 579–585 (2008). https://doi.org/10.1007/s00280-007-0509-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0509-5

Keywords

Search

Navigation